Logo image of 1REGN.MI

REGENERON PHARMACEUTICALS (1REGN.MI) Stock Price, Quote, News and Overview

BIT:1REGN - Euronext Milan - US75886F1075 - Common Stock - Currency: EUR

481.5  -53.7 (-10.03%)

1REGN.MI Quote, Performance and Key Statistics

REGENERON PHARMACEUTICALS

BIT:1REGN (5/9/2025, 7:00:00 PM)

481.5

-53.7 (-10.03%)

Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology
Statistics
52 Week HighN/A
52 Week LowN/A
Market Cap52.64B
Shares109.32M
Float105.65M
Yearly DividendN/A
Dividend Yield0.52%
PE11.72
Fwd PE12.31
Earnings (Next)04-30 2025-04-30/bmo
IPO04-02 1991-04-02


1REGN.MI short term performance overview.The bars show the price performance of 1REGN.MI in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -10 -20 -30 -40

1REGN.MI long term performance overview.The bars show the price performance of 1REGN.MI in the last 1, 2 and 3 years. 1 year 2 years 3 years

The current stock price of 1REGN.MI is 481.5 EUR.

REGENERON PHARMACEUTICALS / 1REGN Daily stock chart

1REGN.MI Competitors/Peers

The largest stocks on the EU markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
4AB.DE ABBVIE INC 18.18 297.54B
AMG.DE AMGEN INC 12.96 130.25B
1GILD.MI GILEAD SCIENCES INC 13.27 115.15B
GIS.DE GILEAD SCIENCES INC 13.07 113.46B
VX1.DE VERTEX PHARMACEUTICALS INC N/A 100.74B
ARGX.BR ARGENX SE 101.39 29.84B
22UA.DE BIONTECH SE-ADR N/A 20.71B
IDP.DE BIOGEN INC 7.71 16.10B
1MRNA.MI MODERNA INC N/A 8.90B
0QF.DE MODERNA INC N/A 8.88B
BIO.DE BIOTEST AG 65.54 1.69B
GLPG.AS GALAPAGOS NV N/A 1.52B

About 1REGN.MI

Company Profile

1REGN logo image Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 13,450 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Company Info

REGENERON PHARMACEUTICALS

777 Old Saw Mill River Road

Tarrytown NEW YORK US

Employees: 13926

1REGN Company Website

1REGN Investor Relations

Phone: 17813705000

REGENERON PHARMACEUTICALS / 1REGN.MI FAQ

What is the stock price of REGENERON PHARMACEUTICALS today?

The current stock price of 1REGN.MI is 481.5 EUR. The price decreased by -10.03% in the last trading session.


What is the ticker symbol for REGENERON PHARMACEUTICALS stock?

The exchange symbol of REGENERON PHARMACEUTICALS is 1REGN and it is listed on the Euronext Milan exchange.


On which exchange is 1REGN.MI stock listed?

1REGN.MI stock is listed on the Euronext Milan exchange.


What is the price forecast or stock price prediction for REGENERON PHARMACEUTICALS stock?

34 analysts have analysed 1REGN.MI and the average price target is 976.66 EUR. This implies a price increase of 102.84% is expected in the next year compared to the current price of 481.5. Check the REGENERON PHARMACEUTICALS stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is REGENERON PHARMACEUTICALS worth?

REGENERON PHARMACEUTICALS (1REGN.MI) has a market capitalization of 52.64B EUR. This makes 1REGN.MI a Large Cap stock.


How many employees does REGENERON PHARMACEUTICALS have?

REGENERON PHARMACEUTICALS (1REGN.MI) currently has 13926 employees.


Is REGENERON PHARMACEUTICALS (1REGN.MI) expected to grow?

The Revenue of REGENERON PHARMACEUTICALS (1REGN.MI) is expected to grow by 3.48% in the next year. Check the estimates tab for more information on the 1REGN.MI EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy REGENERON PHARMACEUTICALS (1REGN.MI) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does REGENERON PHARMACEUTICALS (1REGN.MI) stock pay dividends?

REGENERON PHARMACEUTICALS (1REGN.MI) has a dividend yield of 0.52%. The yearly dividend amount is currently 0. Check the full fundamental report for a detailed analysis of 1REGN.MI dividend history, reliability and sustainability.


When does REGENERON PHARMACEUTICALS (1REGN.MI) report earnings?

REGENERON PHARMACEUTICALS (1REGN.MI) will report earnings on 2025-04-30, before the market open.


What is the Price/Earnings (PE) ratio of REGENERON PHARMACEUTICALS (1REGN.MI)?

The PE ratio for REGENERON PHARMACEUTICALS (1REGN.MI) is 11.72. This is based on the reported non-GAAP earnings per share of 41.09 and the current share price of 481.5 EUR. Check the full fundamental report for a full analysis of the valuation metrics for 1REGN.MI.


1REGN.MI Technical Analysis

ChartMill assigns a technical rating of 2 / 10 to 1REGN.MI.


Chartmill TA Rating
Chartmill Setup Rating

1REGN.MI Fundamental Analysis

ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI. 1REGN.MI scores excellent points on both the profitability and health parts. This is a solid base for a good stock.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

1REGN.MI Financial Highlights

Over the last trailing twelve months 1REGN.MI reported a non-GAAP Earnings per Share(EPS) of 41.09. The EPS increased by 4.25% compared to the year before.


Industry RankSector Rank
PM (TTM) 31.07%
ROA 11.69%
ROE 15.03%
Debt/Equity 0.09
Chartmill High Growth Momentum
EPS Q2Q%1.77%
Sales Q2Q%10.34%
EPS 1Y (TTM)4.25%
Revenue 1Y (TTM)8.27%

1REGN.MI Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 78% to 1REGN.MI. The Buy consensus is the average rating of analysts ratings from 34 analysts.

For the next year, analysts expect an EPS growth of -4.81% and a revenue growth 3.48% for 1REGN.MI


Ownership
Inst Owners89.84%
Ins Owners1.55%
Short Float %N/A
Short RatioN/A
Analysts
Analysts78.24
Price Target976.66 (102.84%)
EPS Next Y-4.81%
Revenue Next Year3.48%